---
title: "Axogen, Inc. (AXGN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AXGN.US.md"
symbol: "AXGN.US"
name: "Axogen, Inc."
industry: "Health Care Equipment"
datetime: "2026-05-20T03:57:14.442Z"
locales:
  - [en](https://longbridge.com/en/quote/AXGN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AXGN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AXGN.US.md)
---

# Axogen, Inc. (AXGN.US)

## Company Overview

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [www.axogeninc.com](https://www.axogeninc.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: B (0.36)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 22 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 22.41% |  |
| Net Profit YoY | -339.10% |  |
| P/B Ratio | 9.11 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2230809716.80 |  |
| Revenue | 238105000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -17.96% | E |
| Profit Margin | -13.21% | D |
| Gross Margin | 75.16% | A |
| Revenue YoY | 22.41% | A |
| Net Profit YoY | -339.10% | E |
| Total Assets YoY | 47.57% | A |
| Net Assets YoY | 132.34% | A |
| Cash Flow Margin | -49.46% | E |
| OCF YoY | 22.41% | A |
| Turnover | 0.98 | A |
| Gearing Ratio | 15.43% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Axogen, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "22.41%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-339.10%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "9.11",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2230809716.80",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "238105000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "-17.96%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-13.21%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "75.16%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "22.41%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-339.10%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "47.57%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "132.34%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-49.46%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "22.41%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.98",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "15.43%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -72.18 | 161/183 | - | - | - |
| PB | 9.27 | 123/183 | 12.78 | 9.00 | 5.66 |
| PS (TTM) | 9.53 | 113/183 | 7.66 | 5.25 | 3.09 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Electromed (ELMD.US) | A | B | A | A | B | A |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | C | C | C | B | B |
| 05 | Boston Scientific (BSX.US) | A | B | C | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-17T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 78% |
| Overweight | 2 | 22% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 42.69 |
| Highest Target | 55.00 |
| Lowest Target | 48.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AXGN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AXGN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AXGN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AXGN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**